275 related articles for article (PubMed ID: 33628588)
1. Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.
Zhang J; Sun B; Ruan X; Hou X; Zhi J; Meng X; Zheng X; Gao M
Cancer Biol Med; 2021 Feb; 18(1):105-119. PubMed ID: 33628588
[TBL] [Abstract][Full Text] [Related]
2. Down-Regulation of HBXIP Inhibits Non-Small Cell Lung Cancer Growth and Enhances the Anti-Tumor Immunity of Mice by Reducing NRP-1.
Wang L; Sun M; Lin X; Lei Y; Yin Z; Zhou W
Ann Clin Lab Sci; 2021 Jul; 51(4):487-493. PubMed ID: 34452886
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.
Wei CH; Wu G; Cai Q; Gao XC; Tong F; Zhou R; Zhang RG; Dong JH; Hu Y; Dong XR
J Hematol Oncol; 2017 Jun; 10(1):125. PubMed ID: 28629431
[TBL] [Abstract][Full Text] [Related]
4. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
5. HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer.
Wang Y; Li N; Che S; Jin T; Piao J; Liu S; Lin Z
Tumour Biol; 2017 Jul; 39(7):1010428317709675. PubMed ID: 28718367
[TBL] [Abstract][Full Text] [Related]
6. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
7. EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in non‑small cell lung cancer cells.
Gao L; Yang T; Zhang S; Liang Y; Shi P; Ren H; Hou P; Chen M
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33907840
[TBL] [Abstract][Full Text] [Related]
8. Highly expressed long non-coding RNA CRNDE promotes cell proliferation through PI3K/AKT signalling in non-small cell lung carcinoma.
Liu XX; Xiong HP; Huang JS; Qi K; Xu JJ
Clin Exp Pharmacol Physiol; 2017 Aug; 44(8):895-902. PubMed ID: 28477368
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. Inhibition of FASN suppresses the malignant biological behavior of non-small cell lung cancer cells via deregulating glucose metabolism and AKT/ERK pathway.
Chang L; Fang S; Chen Y; Yang Z; Yuan Y; Zhang J; Ye L; Gu W
Lipids Health Dis; 2019 May; 18(1):118. PubMed ID: 31122252
[TBL] [Abstract][Full Text] [Related]
11. Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in Non-Small Cell Lung Cancer via Regulation of the miR-661/eEF2K Signaling Pathway.
Gu H; Chen J; Song Y; Shao H
Cell Physiol Biochem; 2018; 51(5):2136-2147. PubMed ID: 30522114
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC.
Chen W; Wang J; Liu S; Wang S; Cheng Y; Zhou W; Duan C; Zhang C
J Exp Clin Cancer Res; 2016 May; 35():76. PubMed ID: 27164951
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical Small GTPase RBJ Promotes NSCLC Progression Through the Canonical MEK/ERK Signaling Pathway.
Wang Y; Shen X; Wang Q; Guo Z; Hu L; Dong Z; Hu W
Curr Pharm Des; 2022; 28(42):3446-3455. PubMed ID: 36397632
[TBL] [Abstract][Full Text] [Related]
14. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9.
Dong QZ; Wang Y; Tang ZP; Fu L; Li QC; Wang ED; Wang EH
Am J Pathol; 2013 Mar; 182(3):954-64. PubMed ID: 23306155
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway.
Lu L; Liu Q; Wang P; Wu Y; Liu X; Weng C; Fang X; Li B; Cao X; Mao H; Wang L; Guan M; Wang W; Liu G
BMC Cancer; 2019 Mar; 19(1):209. PubMed ID: 30849960
[TBL] [Abstract][Full Text] [Related]
16. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA SDPR-AS affects the development of non-small cell lung cancer by regulating SDPR through p38 MAPK/ERK signals.
Zhu J; Wang L; Liao R
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3172-3179. PubMed ID: 31352804
[TBL] [Abstract][Full Text] [Related]
18. ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer.
Li Y; Ye Z; Chen S; Pan Z; Zhou Q; Li YZ; Shuai WD; Kuang CM; Peng QH; Shi W; Mao X; Liu RY; Huang W
Int J Cancer; 2018 Apr; 142(7):1379-1391. PubMed ID: 29164615
[TBL] [Abstract][Full Text] [Related]
19. SRPX2 promotes cell proliferation and invasion via activating FAK/SRC/ERK pathway in non-small cell lung cancer.
Li X; Liu J; Sun H; Zou Y; Chen J; Chen Y; Chen C; Wu X
Acta Biochim Pol; 2020 Jun; 67(2):165-172. PubMed ID: 32550700
[TBL] [Abstract][Full Text] [Related]
20. Mogrol-mediated enhancement of radiotherapy sensitivity in non-small cell lung cancer: a mechanistic study.
Yin Z; Zhang X; Sun X; Huo Y; Ji N; Chen K
Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1753-C1768. PubMed ID: 38682239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
